OCR, NCT00743509: A Phase II Study of Oral Cyclophosphamide and Sirolimus () in Advanced Sarcoma |
|
|
| Completed | 2 | 49 | US | Cyclophosphamide and Sirolimus, Sirolimus (rapamycin, Rapamune) | University of Michigan Rogel Cancer Center | Osteosarcoma | 04/10 | 09/12 | | |
NCT01614795: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma |
|
|
| Completed | 2 | 46 | Canada, US | Cixutumumab, Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12, IMC-A12, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel | National Cancer Institute (NCI) | Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Gliosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Peripheral Nerve Sheath Tumor, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Osteosarcoma, Rhabdomyosarcoma | 04/14 | 04/14 | | |
NCT01016015: Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma |
|
|
| Completed | 2 | 178 | US, Canada | Cixutumumab, Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12, IMC-A12, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel | National Cancer Institute (NCI) | Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Osteosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma | 07/14 | 07/14 | | |
NCT00949325: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma |
|
|
| Completed | 1/2 | 24 | US | temsirolimus plus liposomal doxorubicin, Torisel, Doxil | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Comprehensive Cancer Network, Wyeth is now a wholly owned subsidiary of Pfizer | Sarcoma | 09/12 | 09/12 | | |
